image
Healthcare - Biotechnology - NASDAQ - US
$ 0.2593
-5.74 %
$ 6.96 M
Market Cap
-0.08
P/E
CASH FLOW STATEMENT
-110 M OPERATING CASH FLOW
10.85%
37.3 M INVESTING CASH FLOW
-44.43%
43.5 M FINANCING CASH FLOW
-66.83%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Syros Pharmaceuticals, Inc.
image
Net Income -165 M
Depreciation & Amortization 2.25 M
Capital Expenditures -272 K
Stock-Based Compensation 10.4 M
Change in Working Capital 5.06 M
Others 35.4 M
Free Cash Flow -110 M

Cash Flow

Millions
Dec-2023 Dec-2022 Dec-2021 Dec-2020 Dec-2019 Dec-2018 Dec-2017 Dec-2016 Dec-2015 Dec-2014 Dec-2013
OPERATING CASH FLOW
Net Income (164.6) (94.7) (86.6) (84.0) (75.4) (62.3) (54.0) (47.7) (29.8) (13.4) (8.7)
Depreciation & Amortization 2.3 3.0 3.0 3.0 2.7 1.6 1.5 1.3 0.6 0.3 0.2
Deferred Income Tax 0 0 (16.5) 0.3 (1.1) 0 0 0 0 0 0
Stock Based Compensation 10.4 11.4 10.4 10.9 9.8 6.6 4.4 4.2 3.2 0.9 0.8
Other Operating Activities 37.1 (37.3) 0.7 2.3 7.2 (0.6) (0.1) 10 K 17 K 0.3 0.4
Change in Working Capital 5.1 (5.5) (10.6) 10.1 (3.5) 14.4 3.4 1.7 2.9 0.3 86 K
Cash From Operations (109.7) (123.1) (99.5) (57.4) (60.3) (40.3) (44.7) (40.5) (23.0) (12.0) (7.2)
INVESTING CASH FLOW
Capital Expenditures (0.3) (1.2) (1.2) (3.3) (12.6) (1.4) (0.8) (2.3) (1.2) (0.2) (0.9)
Other Items 37.6 68.4 (51.4) 50.0 0.9 (9.3) (14.8) (25.0) 0 0 0
Cash From Investing Activities 37.3 67.2 (52.7) 46.7 (11.7) (10.6) (15.6) (27.3) (1.2) (0.2) (0.9)
FINANCING CASH FLOW
Common Stock Repurchased 0 81 K 0 0 0 0 0 0 (0.6) 0 0
Total Debt Repaid 65 K (0.3) (0.3) 39.4 (0.2) 50 K (0.2) (0.1) 50 K 0 0
Dividends Paid 0 0 0 0 0 0 0 0 0 0 0
Other Financing Activities 0.3 11.7 0.4 1.3 5.0 0.6 1.8 40.2 0.4 137.5 10.0
Cash From Financing Activities 43.5 131.0 70.5 143.0 66.0 69.1 33.9 90.6 (0.3) 68.8 10.0
CHANGE IN CASH
Net Change In Cash (28.9) 75.2 (81.7) 132.3 (6.0) 18.1 (26.4) 22.7 (24.5) 56.6 2.0
FREE CASH FLOW
Free Cash Flow (110.0) (124.3) (100.8) (60.7) (72.9) (41.7) (45.5) (42.9) (24.2) (12.2) (8.1)